Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Bendamustine, Rituximab in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).